Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE: 002294)
Health Care · Pharmaceuticals · CN
CN¥30.66
+1.46% today · -47.1% 1Y
Shenzhen Salubris Pharmaceuticals Co., Ltd. (SZSE: 002294) operates in the Pharmaceuticals industry within the Health Care sector. The company is valued at $5.07B and employs 4,087 people.
Over the last twelve months the share price has lost 47.1%, trading between 29.25 and 70.99.
Tweenvest scores Shenzhen Salubris Pharmaceuticals Co., Ltd. across four factors: quality 75/100, value 59/100, growth 49/100, dividend 34/100. Its strongest factor is quality.
002294 price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $5.07B
- Revenue (TTM)
- $692.03M
- P/E
- 51.13
- EPS
- 0.60
- Dividend yield
- 1.79%
- Beta (5Y)
- -0.21
- 52-week high
- CN¥70.99
- 52-week low
- CN¥29.25
- Avg volume (3M)
- —
- Shares outstanding
- 1.11B
- Employees
- 4,087
- Next earnings
- —
About Shenzhen Salubris Pharmaceuticals Co., Ltd.
Established in 1998 and headquartered in Shenzhen, China, Shenzhen Salubris Pharmaceuticals Co., Ltd. operates across the entire pharmaceutical value chain, from research and development to manufacturing and sales. The company primarily focuses on critical therapeutic areas within China, including cardiovascular, anti-diabetic, anti-cancer, and orthopedic medicine. Its diverse product portfolio features a variety of cardiovascular and cerebrovascular medications, such as allisartan isoproxil and clopidogrel bisulfate tablets, alongside injectable options like bivalirudin. A significant offering is the recombinant SeV-hFGF2/dF Injection, specifically developed for the treatment of diabetic foot disease. Salubris also manufactures anti-tumor and orthopedic drugs. Furthermore, its anti-infective range encompasses numerous injectable antibiotics, including ceftazidime and ceftriaxone sodium, as well as oral preparations such as azithromycin dispersible and levetiracetam tablets. The firm also innovates in biotechnological drugs, developing recombinant proteins and monoclonal antibodies. Complementing its domestic operations, Shenzhen Salubris Pharmaceuticals engages in the import, in-licensing, and out-licensing of medicines, particularly for European markets.
- ISIN
- CNE100000FW8
- Founded
- 1998
- Listed since
- Sep 10, 2009
- Exchange
- Shenzhen Stock Exchange
- Currency
- CNY
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Ligand Pharmaceuticals IncorporatedNasdaqGM: LGND | $6.04B | $282.73 | -6.68% |
| China Resources Sanjiu Medical & Pharmaceutical Co., Ltd.SZSE: 000999 | $6.00B | CN¥24.19 | +3.20% |
| Abbott India LimitedBSE: 500488 | $5.92B | Rs26,832.10 | -0.38% |
| Ipca Laboratories LimitedNSEI: IPCALAB | $5.12B | Rs1,943.20 | -1.40% |
| Gland Pharma LimitedNSEI: GLAND | $4.92B | Rs2,874.40 | -1.47% |
| GlaxoSmithKline Pharmaceuticals LimitedBSE: 500660 | $4.88B | Rs2,774.50 | -1.50% |
| Veradermics, IncorporatedNYSE: MANE | $4.88B | $128.72 | +10.24% |
| Beijing Tongrentang Co., LtdSHSE: 600085 | $4.85B | CN¥23.74 | +1.71% |
Figures last refreshed Oct 4, 2026.